A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26).
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms EXTRA
- Sponsors Novartis
- 14 May 2010 Actual patient number (218) added as reported by ClinicalTrials.gov.
- 14 May 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.